Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2013

View Archived Issues

Genzyme evaluates rhASM in new phase II trials for ASD

Update on phase I trial shows BP-100-1.01 to be well tolerated and potentially active

Cell Cure Neurosciences receives grant from Israel's OCS

New associations of SHANK3 gene duplications with hyperkinetic neuropsychiatric disorders

Takeda enters agreement with MMV to develop novel antimalarial compounds

Lycera Corp. discloses new inhibitors of F1F0-ATPase

Final data reported from phase II study of Axelar's AXL-1717

Plexxikon plans study of new drug for advanced solid tumors and hairy cell leukemia

NAMPT as a new genetic marker associated with susceptibility, severity and outcome of CAD

Veloxis seeks U.S. approval of Envarsus

OphthaliX reports topline phase III results for CF-101 in dry eye syndrome

Evolva and Serodus sign EV-077 licensing agreement

Phase II results presented for the new oral combination of faldaprevir, deleobuvir and PPI-668

VHRI and Grifols collaborate to create center of excellence in alpha-1-antitrypsin deficiency

Lundbeck's vortioxetine approved in Europe

Scientists at Actelion Pharmaceuticals patent new OX1/OX2 receptor antagonists

Biogen Idec and Sunesis Pharmaceuticals present novel BTK inhibitors

Danish group patents new GPR120 ligands

Target enrollment reached in phase II trial of PI-88

PP-1-12: a novel candidate for suppressing myocardial apoptosis induced by ERS

Senesco Technologies agrees to terms of intent-to-merge letter with Fabrus

FDA accepts tedizolid NDA for priority review

FDA clearance for AmpliVue Group B Strep assay

Novel autotaxin inhibitors synthesized by Roche

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...